Hematological Toxicities
Leadership
Chair
Nikolaos Tsoukalas, MD, MSc, PhD
Greece
Vice-Chair
Nandita Khera, MD, MPH
USA
About
The Hematological Toxicities Study Group focuses on addressing common adverse effects on the blood and blood-forming tissues, which include myelosuppression, infections, immune suppression, hemostasis, and other blood disorders associated with cancer and anti-cancer treatments. The study group focuses on the development of research studies, guidelines and educational initiatives to provide leadership in continual improvement of supportive care and treatment outcomes.
This study group was formed from the merger of the Hemostasis Study Group and the Neutopenia, Infection & Myelosuppression Study Group.
How to Join
To join a study group, you must be a MASCC member. Members can belong to up to three study groups.Â
Guidelines
Evidence-based clinical practice guidelines created by the Hematological Toxicities Study Group